Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: Insights from the REVEAL Registry

Journal of Heart and Lung Transplantation

Volumn 32, Issue 11, 2013, Pages 1114-1122

  Farber, Harrison W ^a   Miller, Dave P ^b   Meltzer, Leslie A ^c   McGoon, Michael D ^d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ICON Late Phase and Outcomes Research   (United States)

^c Actelion Pharmaceuticals US Inc   (United States)

^d MAYO CLINIC   (United States)

Author keywords

pharmacology; prognosis; pulmonary hypertension; registries; survival

Indexed keywords

PROSTACYCLIN;

ADULT; ARTICLE; DETERIORATION; FEMALE; FUNCTIONAL STATUS; HUMAN; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEW YORK HEART ASSOCIATION CLASS; PATIENT ASSESSMENT; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; SENSITIVITY ANALYSIS; TIME OF DEATH; TREATMENT DURATION;

PHARMACOLOGY; PROGNOSIS; PULMONARY HYPERTENSION; REGISTRIES; SURVIVAL;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; AGED; DISEASE MANAGEMENT; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, PARENTERAL; INFUSIONS, SUBCUTANEOUS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PULMONARY WEDGE PRESSURE; RECEPTORS, ENDOTHELIN; REGISTRIES; SURVIVAL RATE;

EID: 84885954778     PISSN: 10532498     EISSN: 15573117     Source Type: Journal    
DOI: 10.1016/j.healun.2013.08.010     Document Type: Article

References (39)

1. V.V. McLaughlin, S.L. Archer, and D.B. Badesch ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association J Am Coll Cardiol 53 2009 1573 1619
2. D.B. Badesch, S.H. Abman, G. Simonneau, L.J. Rubin, and V.V. McLaughlin Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines Chest 131 2007 1917 1928
3. M. Humbert, N.W. Morrell, and S.L. Archer Cellular and molecular pathobiology of pulmonary arterial hypertension J Am Coll Cardiol 43 2004 13 24S
4. G.E. D'Alonzo, R.J. Barst, and S.M. Ayres Survival in patients with primary pulmonary hypertension. Results from a national prospective registry Ann Intern Med 115 1991 343 349
5. N. Galie, D. Badesch, and R. Oudiz Ambrisentan therapy for pulmonary arterial hypertension J Am Coll Cardiol 46 2005 529 535
6. R.J. Barst, D. Langleben, and A. Frost Sitaxsentan therapy for pulmonary arterial hypertension Am J Respir Crit Care Med 169 2004 441 447
7. G. Simonneau, R.J. Barst, and N. Galie Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial Am J Respir Crit Care Med 165 2002 800 804
8. R.N. Channick, G. Simonneau, and O. Sitbon Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study Lancet 358 2001 1119 1123
9. R.J. Barst, L.J. Rubin, and W.A. Long A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group N Engl J Med 334 1996 296 302
10. N. Galie, M.M. Hoeper, and M. Humbert Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2009 2493 2537
11. M. Humbert, O. Sitbon, and G. Simonneau Treatment of pulmonary arterial hypertension N Engl J Med 351 2004 1425 1436
12. K.B. Highland Pulmonary arterial hypertension Am J Med Sci 335 2008 40 45
13. V.V. McLaughlin, A. Shillington, and S. Rich Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 106 2002 1477 1482
14. R. Barst How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension? Int J Clin Pract Suppl 2010 23 32
15. L. Zhao, N.A. Mason, and N.W. Morrell Sildenafil inhibits hypoxia-induced pulmonary hypertension Circulation 104 2001 424 428
16. B.K. Sastry, C. Narasimhan, N.K. Reddy, and B.S. Raju Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study J Am Coll Cardiol 43 2004 1149 1153
17. L.J. Rubin, D.B. Badesch, and R.J. Barst Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 2002 896 903
18. L.J. Rubin, J. Mendoza, and M. Hood Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial Ann Intern Med 112 1990 485 491
19. D.B. Badesch, V.F. Tapson, and M.D. McGoon Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease A randomized, controlled trial. Ann Intern Med 132 2000 425 434
20. R.L. Benza, M.H. Park, A. Keogh, and R.E. Girgis Management of pulmonary arterial hypertension with a focus on combination therapies J Heart Lung Transplant 26 2007 437 446
21. H.A. Ghofrani, R. Wiedemann, and F. Rose Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension Ann Intern Med 136 2002 515 522
22. M.M. Hoeper, N. Taha, A. Bekjarova, R. Gatzke, and E. Spiekerkoetter Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids Eur Respir J 22 2003 330 334
23. M.M. Hoeper, H. Leuchte, and M. Halank Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Eur Respir J 28 2006 691 694
24. V.V. McLaughlin, R.J. Oudiz, and A. Frost Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension Am J Respir Crit Care Med 174 2006 1257 1263
25. O.A. Minai, and A.C. Arroliga Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan South Med J 99 2006 880 883
26. R.L. Benza, B.K. Rayburn, J.A. Tallaj, S.V. Pamboukian, and R.C. Bourge Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan Chest 134 2008 139 145
27. M.D. McGoon, A. Krichman, and H.W. Farber Design of the REVEAL registry for US patients with pulmonary arterial hypertension Mayo Clin Proc 83 2008 923 931
28. D.B. Badesch, G.E. Raskob, and C.G. Elliott Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry Chest 137 2010 376 387
29. N. Galie, A. Torbicki, and R. Barst Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur Heart J 25 2004 2243 2278
30. G. Simonneau, I.M. Robbins, and M. Beghetti Updated clinical classification of pulmonary hypertension J Am Coll Cardiol 54 2009 S43 S54
31. A.E. Frost, D.B. Badesch, and R.J. Barst The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries Chest 139 2011 128 137
32. K.D Kochanek, J. Xu, S.L Murphy, A.M. Miniño, and H.-C Kung Deaths: final data for 2009 Natl Vital Stat Rep 60 2012 1 117
33. D.B. Badesch, S.H. Abman, and G.S. Ahearn Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines Chest 126 2004 35S 62S
34. R.J. Barst, L.J. Rubin, M.D. McGoon, E.J. Caldwell, W.A. Long, and P.S. Levy Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin Ann Intern Med 121 1994 409 415
35. O. Sitbon, M. Humbert, and H. Nunes Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival J Am Coll Cardiol 40 2002 780 788
36. J.L. Vachiery Prostacyclins in pulmonary arterial hypertension: the need for earlier therapy Adv Ther 28 2011 251 269
37. M.M. Hoeper, C. Faulenbach, H. Golpon, J. Winkler, T. Welte, and J. Niedermeyer Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Eur Respir J 24 2004 1007 1010
38. M. Humbert, R.J. Barst, and I.M. Robbins Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Eur Respir J 24 2004 353 359
39. G. Simonneau, L.J. Rubin, and N. Galie Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial Ann Intern Med 149 2008 521 530